Results 211 to 220 of about 159,305 (301)

Risk factors for sudden cardiac death or sudden unexplained death in patients treated with clozapine: systematic review. [PDF]

BJPsych Open
Easwar T, Chari D, Abdullah S, Tollinton H, Ladinska EBM, Subramaniam HE.   +5 more
europepmc   +1 more source

Continuous Positive Airway Pressure Versus Mandibular Advancement Devices Impact on Cardio‐Metabolic Outcomes in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Journal of Sleep Research, EarlyView.
ABSTRACT Obstructive sleep apnea contributes to cardiovascular morbidity, and its treatment may mitigate this risk. Continuous positive airway pressure and mandibular advancement devices are established therapies, but their comparative cardiometabolic effects remain uncertain.
AlMothana Manasrah, Mohammad Tanashat, Ramy Ghaly, Mohamed Abouzid, Shrouq Ramadan, Abdo‐rhman Khassawneh, Abubakar Nazir, Zaid Bataineh, Mohammed Ayyad, Mohamed Abuelazm, Basel Abdelazeem, Muhammad Imran Ali   +11 more
wiley   +1 more source

Pharmacokinetics of 2 mg/kg Bupivacaine in a Rectus Abdominis Sheath Block in Horses

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Administering large volumes of bupivacaine in the rectus abdominis sheath (RAS) block in horses could cause local anesthetic toxicity. This study aimed to evaluate the pharmacokinetics of 2 mg/kg bupivacaine in RAS blocks and the associated toxicity risk.
Daniel M. Sakai, Yushun Ishikawa, Jessica S. Y. Im, Shufan Zhang, Rachel A. Reed, Jane E. Quandt, Michele Barletta, Heather K. Knych   +7 more
wiley   +1 more source

Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Cardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown. Methods A retrospective analysis was conducted using the
Bilal Hussain, Sanchit Duhan, Khawaja Hassan Akhtar, Amith Reddy Seri, Krittapoom Akrawinthawong, Janardhana Gorthi, Bijeta Keisham, Tarun Dasari   +7 more
wiley   +1 more source

QTc Interval Prolongation and Associated Drug Therapy in Hospitalized Older Adults

Journal of the American Geriatrics Society, EarlyView.
Francesco Fantin, Sara Fiorini, Anna Giani, Luana Giacobbe, Elena Zoico, Gianluca Trifirò, Rocco Micciolo, Mauro Zamboni   +7 more
wiley   +1 more source

Incidence and Determinants of Implantable Cardioverter‐Defibrillator Therapy With Loss of and Impaired Consciousness

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Implantable cardioverter‐defibrillators (ICDs) are important in the prevention of sudden cardiac death. However, some appropriate ICD therapies may be considered unnecessary, delivered when patients do not experience symptoms of hemodynamic instability such as loss of consciousness.
Alwin B. P. Noordman, Michiel Rienstra, Yuri Blaauw, Bart A. Mulder, Hessel Groenveld, Alexander H. Maass   +5 more
wiley   +1 more source

QT Interval Evaluation in Right Ventricular Pacing: Validation of a Novel Formula

Pacing and Clinical Electrophysiology, EarlyView.
Abstract Background QT interval measurement in the presence of right ventricular pacing (RVP) represents a clinical challenge. We therefore aimed to derive and validate a formula for QT estimation during RVP in a large cohort of pacemaker patients. Methods and Results We prospectively enrolled 100 patients in a derivation cohort and 487 in a validation
Amr Abdin, Alhasan Almasri, Ibrahim Antoun, Charles Gieres, Christian Werner, Yvonne Bewarder, Christian Ukena, Igor Schwantke, Michael Böhm, Saarraaken Kulenthiran   +9 more
wiley   +1 more source

Safety and Performance of INVICTA DF4 Ventricular Defibrillation Lead: Results From APOLLO Prospective Multicenter Study

Pacing and Clinical Electrophysiology, EarlyView.
Abstract Background Implantable cardioverter‐defibrillator (ICD) therapy relies on reliable right ventricular leads for pacing, sensing, and defibrillation. The INVICTA DF4 lead is an active‐fixation, quadripolar design intended to optimize implant workflow and long‐term safety and performance. Methods APOLLO was a prospective, multicenter, single‐arm,
Klaus K. Witte, Juan Gabriel Martínez, Mário M. Oliveira, Alberto Barrera, Maite Izquierdo, Cosimo Mandurino, Maria Emilce Trucco, José Juan García Salvador, Antoine Dompnier, Frédéric Jean, Pablo J. Sánchez Millán, Carsten Israel, Maria Martino, Pedro Marques   +13 more
wiley   +1 more source

First Experience With Extravascular Implantable Cardioverter‐Defibrillator Under Deep Sedation

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The Extravascular Implantable Cardioverter‐Defibrillator (EV‐ICD) utilizes a substernal lead to provide defibrillation and anti‐tachycardia pacing (ATP) while avoiding transvenous complications. General anesthesia (GA) was applied for implantation procedures in the EV‐ICD pivotal trial and is currently recommended by the ...
Nibras Soubh, Bernhard C. Danner, Ulrich Krause, Matthias J. Müller, Markus Zabel, Gerd Hasenfuß, Constanze Schmidt, Helge Haarmann, Eva Rasenack, Leonard Bergau   +9 more
wiley   +1 more source